<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30904438</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>7</Issue><PubDate><Year>2019</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Human immunology</Title><ISOAbbreviation>Hum Immunol</ISOAbbreviation></Journal><ArticleTitle>Patients with immunological diseases or on peritoneal dialysis are prone to false positive flow cytometry crossmatch.</ArticleTitle><Pagination><StartPage>487</StartPage><EndPage>492</EndPage><MedlinePgn>487-492</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.humimm.2019.03.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0198-8859(18)31099-1</ELocationID><Abstract><AbstractText>Despite implementation of virtual crossmatches, flow cytometry crossmatches (FCXM) are still used by many transplant centers to determine immunological risk before kidney transplantation. To determine if common profiles of patients prone to false positive FCXM exist, we examined the demographics and native diseases of kidney patients tested with autologous FCXM (n&#x202f;=&#x202f;480). Improvements to FCXM and cell isolation methods significantly reduced the positive rate from 15.1% to 5.3%. Patients with native diseases considered 'immunological' (vasculitis, lupus, IgA nephropathy) had more positive autologous FCXM (OR&#x202f;=&#x202f;3.36, p&#x202f;=&#x202f;0.003) vs. patients with all other diseases. Patients who were tested using our updated method (n&#x202f;=&#x202f;321) still showed that these immunological diseases were a significant predictor for positive autologous FCXM (OR&#x202f;=&#x202f;4.79, p&#x202f;=&#x202f;0.006). Interestingly, patients on peritoneal dialysis (PD) also had significantly more positive autologous FCXM than patients on hemodialysis or waiting for pre-emptive kidney transplants (OR&#x202f;=&#x202f;3.27, p&#x202f;=&#x202f;0.02). These findings were confirmed in patients who had false positive allogeneic FCXM. Twenty of 24 (83.3%) patients with false positive allogeneic FCXM tested with updated method either had immunological diseases originally or were on PD. Our findings are helpful when interpreting an unexpected positive FCXM, especially for transplantation from deceased donors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qingyong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Pathology and Lab Medicine, London Health Sciences Centre - University Hospital, London, Ontario, Canada; Department of Pathology and Lab Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Multi-Organ Transplant Program, London Health Sciences Centre - University Hospital, London, Ontario, Canada. Electronic address: Qingyong.Xu@lhsc.on.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>House</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Multi-Organ Transplant Program, London Health Sciences Centre - University Hospital, London, Ontario, Canada; Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leckie</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Pathology and Lab Medicine, London Health Sciences Centre - University Hospital, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunaratnam</LastName><ForeName>Lakshman</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Multi-Organ Transplant Program, London Health Sciences Centre - University Hospital, London, Ontario, Canada; Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luke</LastName><ForeName>Patrick P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Multi-Organ Transplant Program, London Health Sciences Centre - University Hospital, London, Ontario, Canada; Department of Surgery, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jevnikar</LastName><ForeName>Anthony M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Multi-Organ Transplant Program, London Health Sciences Centre - University Hospital, London, Ontario, Canada; Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Immunol</MedlineTA><NlmUniqueID>8010936</NlmUniqueID><ISSNLinking>0198-8859</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005922" MajorTopicYN="N">Glomerulonephritis, IGA</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006650" MajorTopicYN="N">Histocompatibility Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="N">Kidney Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010530" MajorTopicYN="Y">Peritoneal Dialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014019" MajorTopicYN="N">Tissue Donors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Flow cytometry crossmatch</Keyword><Keyword MajorTopicYN="N">HLA</Keyword><Keyword MajorTopicYN="N">Transplantation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>2</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30904438</ArticleId><ArticleId IdType="doi">10.1016/j.humimm.2019.03.015</ArticleId><ArticleId IdType="pii">S0198-8859(18)31099-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>